Picture loading failed.

Pre-Made Sintilimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Sintilimab, sold under the brand Tyvyt among others, is a medication used to treat Hodgkin's disease, and has been approved in China.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-523-1mg 1mg 3090
GMP-Bios-ab-523-10mg 10mg 21890
GMP-Bios-ab-523-100mg 100mg 148000
GMP-Bios-ab-523-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Sintilimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
INN Name Sintilimab
TargetPDCD1/PD-1
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesAdimab;Innovent Biologics;Jiangsu Provincial Peoples Hospital;Sun Yat-Sen University
Conditions ApprovedHodgkin's disease
Conditions ActiveGastric cancer;Non-small cell lung cancer;Oesophageal cancer;Liver cancer;Extranodal NK-T-cell lymphoma;Small cell lung cancer;Solid tumours
Conditions Discontinuedna
Development Techna